News

Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the US patents covering Seasonale and Watson is expected to continue marketing its

QuantRx (QN Diagnostics) claimed that this is the first distribution agreement for the company in the animal healthcare market and marks the commercial launch of its first product

Helsinn Group said that Palonosetron (palonosetron hydrochloride) is a second generation 5-HT3 Receptor Antagonist, developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer,

Cleveland BioLabs said that CBLB502 is being developed under the FDA’s Animal Efficacy Rule to treat ARS or radiation poisoning from any exposure to radiation such as a

Rufinamide is a triazole derivative that is structurally unrelated to currently marketed antiepileptic drugs (AEDs). It is believed to exert its antiepileptic effects by regulating the activity of

Eisai Limited is working with Health Canada on the approval of select products from the Eisai portfolio to be introduced in the Canadian market. Eisai said that in

In this newly created role, Mr Berger will be responsible for developing Catalent’s global marketing strategy, implementing marketing excellence across all business units as well as building Catalent’s

The current data suggest that VB-201 has anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the

Silodyx is a new compound indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) and recently approved by the European Medicines Agency (EMA).